The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
Click here to watch it, free.
Michael T. Constantino net worth and biography

Michael Constantino Biography and Net Worth

Director of Humacyte
Mr. Constantino is a retired Ernst & Young LLP assurance partner who served in the Research Triangle Park region of North Carolina for over 30 years. Mr. Constantino holds a B.A. in both Accounting and Business Management from NC State University and is a North Carolina Certified Public Accountant, or CPA. Mr. Constantino is serves as Chair of Humacyte’s Audit Committee.

What is Michael T. Constantino's net worth?

The estimated net worth of Michael T. Constantino is at least $12,510.00 as of May 23rd, 2022. Mr. Constantino owns 4,500 shares of Humacyte stock worth more than $12,510 as of January 30th. This net worth approximation does not reflect any other investments that Mr. Constantino may own. Learn More about Michael T. Constantino's net worth.

How do I contact Michael T. Constantino?

The corporate mailing address for Mr. Constantino and other Humacyte executives is 1177 AVENUE OF THE AMERICAS 5TH FLOOR, NEW YORK NY, 10036. Humacyte can also be reached via phone at 919-313-9633 and via email at [email protected] Learn More on Michael T. Constantino's contact information.

Has Michael T. Constantino been buying or selling shares of Humacyte?

Michael T. Constantino has not been actively trading shares of Humacyte during the last quarter. Most recently, on Monday, May 23rd, Michael T. Constantino bought 2,000 shares of Humacyte stock. The stock was acquired at an average cost of $4.83 per share, with a total value of $9,660.00. Following the completion of the transaction, the director now directly owns 4,500 shares of the company's stock, valued at $21,735. Learn More on Michael T. Constantino's trading history.

Who are Humacyte's active insiders?

Humacyte's insider roster includes Michael Constantino (Director), Brady Dougan (Director), and Laura Niklason (CEO). Learn More on Humacyte's active insiders.

Are insiders buying or selling shares of Humacyte?

During the last twelve months, Humacyte insiders bought shares 7 times. They purchased a total of 51,525 shares worth more than $192,428.00. During the last twelve months, insiders at the sold shares 5 times. They sold a total of 2,461,768 shares worth more than $8,641,540.56. The most recent insider tranaction occured on December, 16th when CFO Dale A Sander bought 20,000 shares worth more than $52,000.00. Insiders at Humacyte own 25.0% of the company. Learn More about insider trades at Humacyte.

Information on this page was last updated on 12/16/2022.

Michael T. Constantino Insider Trading History at Humacyte

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/23/2022Buy2,000$4.83$9,660.004,500View SEC Filing Icon  
11/22/2021Buy2,500$10.79$26,975.00View SEC Filing Icon  
See Full Table

Michael T. Constantino Buying and Selling Activity at Humacyte

This chart shows Michael T Constantino's buying and selling at Humacyte by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Humacyte Company Overview

Humacyte logo
Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs). Its investigational HAVs are designed to be easily implanted into any patient without inducing a foreign body response or leading to immune rejection. The company is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; and coronary artery bypass grafting, as well as developing its HAVs for pediatric heart surgery and cellular therapy delivery, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.
Read More

Today's Range

Now: $2.78
Low: $2.61
High: $2.81

50 Day Range

MA: $2.63
Low: $2.02
High: $3.27

2 Week Range

Now: $2.78
Low: $1.96
High: $8.04

Volume

210,100 shs

Average Volume

211,617 shs

Market Capitalization

$286.67 million

P/E Ratio

8.69

Dividend Yield

N/A

Beta

1.13
Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
click here now to get all the chilling details.